Drug Profile
Influenza A virus vaccine H5N1 intranasal - BioDiem
Alternative Names: Avian (H5N1) intranasal influenza virus vaccine - BioDiem; Intranasal H5N1 influenza virus vaccine - BioDiem/Centers for Disease Control and PreventionLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
- Developer BioDiem; Centers for Disease Control and Prevention
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype in Russia (Intranasal)
- 28 Jan 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype in Thailand (Intranasal)
- 28 Jan 2018 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Intranasal)